Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 18;13:4855. doi: 10.1038/s41467-022-32573-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Number of spot-forming units (SFU) per 1e6 peripheral blood mononuclear cells (PBMCs) following stimulation with M, N, S1, or S2 overlapping peptide pools at indicated timepoints post-diagnosis within the subsample of individuals undergoing detailed testing (total n = 64; W2: n = 56, M1: n = 64, M3: n = 64, M6: n = 55). Boxplots represent the median and interquartile range (IQR; whiskers: 1.5 × IQR). Dotted lines indicate the limit of detection cutoff (SFU values greater than 0). Statistical testing was performed using two-sided Friedman and two-sided Kruskal–Wallis tests to account for both repeated testing and missing data (n = 48 with complete follow-up data). p_F: p-value based on Friedman test, p_KW: p-value based on Kruskal–Wallis test, W2: two weeks, M1: one month, M3: three months, M6: six months after diagnosis. b Fraction of the pooled T cell response (summed M, N, S1, and S2 SFU values) specific for each peptide pool at indicated timepoints post-diagnosis. c Representative flow cytometry plots depicting AIM⁺ (CD134⁺CD137⁺) CD4⁺ (left) and AIM⁺ (CD69⁺CD137⁺) CD8⁺ (right) T cell populations in unstimulated (top) or SARS-CoV-2 megapool peptide-stimulated (bottom) PBMCs. d AIM⁺ cells as a fraction of CD4⁺ or CD8⁺ T cells at indicated timepoints post-diagnosis within the subsample of individuals undergoing detailed testing (total n = 64; W2: n = 46, M1: n = 53, M3: n = 62, M6: n = 54). Boxplots represent median and IQR (whiskers: 1.5 × IQR). Statistical testing was performed using two-sided Friedman (n = 35 with complete follow-up data) and two-sided Kruskal–Wallis tests. e Percentage of AIM⁺CD4⁺ and AIM⁺CD8⁺ T cells with TCM (CD45RA^–CCR7⁺), TEM (CD45RA^–CCR7^–) or TEMRA (CD45RA⁺CCR7^–) phenotypes by day post-diagnosis. Lines represent trends over time based on unadjusted linear regression models. Source data are provided as a Source Data file.